HDAC2 and diffuse large B-cell lymphoma: Our findings demonstrate that Hdac1 can be considered an important factor in Eμ-myc tumorigenesis, and suggest that selective HDAC1 (and HDAC2) inhibitors could be effective for the treatment of BL, as modeled by our preclinical Eμ-myc system, and possibly other hematological malignancies, including some DLBCL.